IRadimed Corporation reported a significant increase in its financial performance for the fiscal year ending December 31, 2025, with total revenue reaching $83.8 million, a 14.4% increase from $73.2 million in 2024. The company's income from operations was $26.1 million, resulting in an operating profit margin of approximately 31.2%. This growth was primarily driven by increased sales of its MRI-compatible medical devices, particularly the MRidium IV infusion pump systems, which saw a revenue increase of 19.0% to $31.6 million, and the 3880 MRI-compatible patient vital signs monitoring systems, which generated $26.4 million in revenue.
Compared to the previous fiscal year, IRadimed's revenue from U.S. sales increased by $10.0 million, or 16.4%, while international sales rose by $0.6 million, or 4.8%. The company sold approximately 13,098 MRI-compatible IV infusion pump system channels and 3,397 patient vital signs monitoring systems as of December 31, 2025. The increase in customer counts and product adoption rates reflects the growing demand for MRI-compatible medical devices, which are essential for patient safety during MRI procedures.
Strategically, IRadimed has made notable advancements, including the introduction of the MRidium 3870 IV infusion pump system, which received FDA 510(k) clearance in May 2025 and began shipping to customers in December 2025. The company also completed the construction of a new 62,000 square foot manufacturing facility in Orlando, Florida, which is expected to support its operational and growth needs. As of December 31, 2025, IRadimed employed 166 full-time staff, an increase from the previous year, reflecting its commitment to expanding its workforce to meet growing demand.
The filing indicates that the company anticipates continued growth in 2026, driven by increased market awareness of its MRI-compatible products and the expansion of its sales efforts into critical care departments within hospitals. However, IRadimed also faces challenges, including reliance on a limited number of products and potential disruptions in its supply chain. The company has emphasized the importance of maintaining regulatory compliance and the integrity of its supply chain to mitigate risks associated with its operations.
Looking ahead, IRadimed's management remains optimistic about the future, citing the potential for further market penetration and the introduction of new products. The company plans to continue investing in research and development to enhance its product offerings and maintain its competitive edge in the MRI-compatible medical device market.
About IRADIMED CORP
Iradimed Corporation develops MRI-compatible medical devices, including infusion pumps and vital signs monitors, designed for safe operation within strong magnetic fields. Its products serve hospitals and critical care facilities worldwide, enabling safe, accurate patient monitoring and fluid delivery during MRI procedures. The company’s innovative, non-magnetic technology offers a competitive advantage in the expanding MRI safety market, focusing on patient safety, workflow efficiency, and regulatory compliance.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.